AMRX — Amneal Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1723128 ·
Last close
$20.50
Market Cap
$7.14B
52W High
$21.17
52W Low
$9.56
ADV30
2,233,606
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 722,519,000 | 320,113,000 | 148,269,000 | 62,256,000 | 3,540,218,000 | 197,656,000 | 3,586,187,000 |
| Dec 2025 | 814,319,000 | 297,190,000 | 114,503,000 | 35,076,000 | 3,678,280,000 | 282,029,000 | 3,749,609,000 |
| Sep 2025 | 784,513,000 | 273,974,000 | 70,487,000 | 2,369,000 | 3,599,874,000 | 201,249,000 | 3,709,829,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$200,778,000
Investing CF
$-212,370,000
Financing CF
$69,629,000
CapEx
$-213,085,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.49
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-415,087,000
Inventory
$677,954,000
Receivables
$1,082,629,000
ST Investments
—
EBIT TTM
$428,633,000
Pretax Income TTM
$201,178,000
Interest Exp TTM
$227,455,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,117,548,032
EBITDA
$689,436,992
Free Cash Flow
$-115,327,128
Enterprise Value
$8,176,514,048
Total Cash
$131,413,000
Total Debt
$2,791,760,896
Shares Out
348,296,027
Trailing EPS
$0.48
Book Value
$0.10
ROE
613.0%
ROA
8.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 3,018,760,000 | 397,914,000 | 72,057,000 | 3,678,280,000 | 3,749,609,000 | -70,794,000 | 339,992,000 |
| Dec 2024 | 2,793,957,000 | 348,373,000 | -116,886,000 | 3,501,445,000 | 3,610,957,000 | -109,267,000 | 295,099,000 |
| Dec 2023 | 2,393,607,000 | 238,747,000 | -83,993,000 | 3,472,569,000 | 3,452,558,000 | 19,781,000 | 345,577,000 |
| Dec 2022 | 2,212,304,000 | 188,922,000 | -129,986,000 | 3,799,341,000 | 3,615,362,000 | 298,421,000 | 65,100,000 |
TTM Snapshot
Revenues TTM
$2,563,485,000
NetIncome TTM
$14,108,000
OpCashFlow TTM
$0
Assets (Latest)
$3,678,280,000
Forward EPS
$1.17
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $17.50 · spot: $20.50 · call volume: 100 · put volume: 2
Expected Move to 2026-10-16:
±$2.13
(10.39%) —
implied range
$18.37 –
$22.63
· ATM straddle on $20.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RYTM | RHYTHM PHARMACEUTICALS, INC. | $6.79B | $98.56 | — |
| SYRE | Spyre Therapeutics, Inc. | $7.56B | $85.79 | — |
| ALKS | Alkermes plc. | $6.74B | $40.15 | — |
| IONS | IONIS PHARMACEUTICALS INC | $7.57B | $45.57 | — |
| BLTE | BELITE BIO, INC | $6.68B | $165.93 | — |
News headlines (Yahoo Finance, 1h cache)
Why Is Amneal (AMRX) Stock Rocketing Higher Today
2026-09-22 00:38 · Yahoo
Amneal Announces FDA Approval and Launch of Lanreotide Injection
2026-09-18 20:01 · Yahoo
3 Reasons to Avoid AMRX and 1 Stock to Buy Instead
2026-09-18 18:00 · Yahoo
Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?
2026-09-17 12:20 · Yahoo
Does Amneal’s Post‑Earnings Shelf Registration Reshape the Bull Case for Amneal Pharmaceuticals (AMRX)?
2026-09-05 07:06 · Yahoo
Amneal Pharmaceuticals (AMRX) Bets Big On Biosimilars While Wall Street Retreats
2026-09-04 18:48 · Yahoo
Amneal Pharmaceuticals (AMRX) Stock Sees Modest Fair Value Lift On Launch Optimism
2026-09-04 16:13 · Yahoo
Generic Pharmaceuticals Stocks Q2 Results: Benchmarking Amneal (NASDAQ:AMRX)
2026-09-03 14:07 · Yahoo
AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study
2026-08-27 14:57 · Yahoo
BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program
2026-08-27 13:42 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.